ArticleNature and science of sleep2025
Temporal Dynamics of Fractional Exhaled Nitric Oxide (FeNO) During CPAP Therapy in Obstructive Sleep Apnea: A Prospective Follow-Up Study.
Article in Nature and science of sleep, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to assess: (i) whether long-term continuous positive airway pressure (CPAP) reduces fractional exhaled nitric oxide (FeNO) in obstructive sleep apnea (OSA), and (ii) how FeNO change relates to baseline OSA severity. Unlike prior cross-sectional work, we performed a prospective longitudinal follow-up with FeNO at baseline, after short-term titration, and at three months. Primary and secondary endpoints were prespecified. Methods: We enrolled 62 patients with moderate-to-severe OSA; 43 completed CPAP titration and three-month follow-up. FeNO was measured preCPAP, after two nights (postCPAP1), and at three months (postCPAP2). Secondary analyses examined correlations between FeNO change and baseline indices-apnea-hypopnea index (AHI), oxygen desaturation index (ODI), percent sleep time with SpO₂ < 90% (TS90%), and Epworth Sleepiness Scale (ESS)-and the effect of CPAP adherence. Statistics: normality (Shapiro-Wilk); Results: At baseline, FeNO was higher in OSA than in AHI < 15 reference subjects from our earlier cohort (21.49 ± 5.56 vs 13.28 ± 3.70 ppb, Conclusion: Sustained CPAP significantly lowers FeNO, reflecting reduced airway inflammation in OSA. FeNO may serve as a promising non-invasive candidate biomarker for monitoring CPAP response, but larger multicenter studies are needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.